(MENAFN- Daily News Egypt) Novo Nordisk company, a world leading healthcare company, announced that Hassan Fahmy became the CEO of the company in July 2017.
Fahmy has more than 20 years of experience in marketing, business development, and communications.
Moreover, he tenured several leadership positions in a number of companies specialised in the consumer sector.
Meanwhile, Fahmy said the company is aiming to growth further and expand its business in the Egyptian market.
'The company also seeks to implement a number of initiatives and activities that aimed at serving the Egyptian patients in cooperation with the Egyptian Ministry of Health,' according to Fahmy.
In the same context, Novo Nordisk has launched several initiatives in recent years in Egypt, such as the launching of Novocare centres that aimed at spreading the awareness of the diabetes and its complications among the diabetics in 16 governorates as well as opening two centres for the diabetes treatment in the cooperation with the Ministry of Health, according to Fahmy.
Moreover, he explained that these centres offer a variety of free healthcare services for diabetics,
including the early detection of the first and second types of the disease, medical advice for the patients and providing a group of doctors specialised in diabetes and the complications that might arise during treatment.
Fahmy stressed that the company creates drugs that changes patients' lives, such as insulin and Victoza drug.
In the same context, Fahmy explained that Tresiba insulin has a more-than-24-hour effect when taken once a day.
Meanwhile, Victoza controls the blood glucose levels for 24 hours when taken once a day.
Novo Nordisk is one of the world's leading companies in healthcare, with more than 90 years of experience in health products and services offered to diabetics.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.